DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Rugo HS, Im SA, Wright GL, Escriva-de-Romani S, DeLaurentiis M, Cortes J.
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M)+ chemotherapy (C) versus trastuzumab (T)+C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
JCO 2019;
37: 1000
Access:
We do not assume any responsibility for the contents of the web pages of other providers.